NEW YORK – Single-cell DNA sequencing firm Mission Bio said on Thursday that it has signed an agreement with China's SequMed to collaborate on services and the development of clinical applications.
Under the terms of the agreement, the firms will work together to combine Mission Bio's Tapestri platform with SequMed's clinical assay development and data analysis capabilities to create new single-cell assays for cancer early detection, therapy selection, and prognosis monitoring. They will also work on applications in reproductive genetics.
"By integrating our single-cell technology with SequMed's expertise in clinical assay development, we are committed to improving diagnosis, prognosis, and treatment of diseases in China," Yan Zhang, CEO of Mission Bio, said in a statement.
SequMed, founded in 2017, is a single-cell genomics services provider based in Guangzhou, China.
Mission Bio, based in South San Francisco, California, has previously partnered with other firms to expand its business in China. Earlier this year, it teamed up with Sequanta Technologies to offer single-cell sequencing services in mainland China, and in 2019, it signed a distribution deal for that country with Novogene.